Get the Stockscreener App
0.387
3.01%
-0.012
After Hours:
.38
-0.007
-1.81%
Aethlon Medical Inc stock is traded at $0.387, with a volume of 105.63K.
It is down -3.01% in the last 24 hours and down -11.72% over the past month.
Aethlon Medical Inc is a medical therapeutic company. The company is focused on addressing unmet needs in health and biodefense. The company is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and eliminate life-threatening viruses from the circulatory system.
See More
Previous Close:
$0.399
Open:
$0.4043
24h Volume:
105.63K
Relative Volume:
0.07
Market Cap:
$5.44M
Revenue:
$294.20K
Net Income/Loss:
$-12.25M
P/E Ratio:
-0.0704
EPS:
-5.5
Net Cash Flow:
$-10.77M
1W Performance:
-0.57%
1M Performance:
-11.72%
6M Performance:
-72.16%
1Y Performance:
-79.30%
1-Day Range:
$0.3804
$0.4043
1-Week Range:
$0.372
$0.4283
52-Week Range:
$0.2375
$2.3499
Aethlon Medical Inc Stock (AEMD) Company Profile
Name
Aethlon Medical Inc
Sector
Industry
Phone
619-941-0360
Address
11555 SORRENTO VALLEY ROAD, SUITE 203, SAN DIEGO, CA
Aethlon Medical Inc Stock (AEMD) Latest News
OTC Markets Hosts Virtual Investor Presentation with Jim Frakes, Interim CEO & CFO, and Steven LaRosa, MD, Chief Medical Officer, of Aethlon Medical Inc., with Marla Marin, Senior Analyst at Zacks SCR - Yahoo Finance
Is Aethlon Medical Inc (AEMD) worth investing in despite its overvalued state? - US Post News
Daily Progress: Aethlon Medical Inc (AEMD) Gain 1.15, Closing at 0.40 - The Dwinnex
Aethlon Medical Inc (AEMD) Q1 2025 Earnings Call Highlights: Strategic Cost Management and ... - Yahoo Finance
Aethlon Medical to Participate in the 2024 Maxim Healthcare Virtual Summit - cnhinews.com
A new trading data show Aethlon Medical Inc (AEMD) is showing positive returns. - SETE News
Deeper Dive: Understanding Aethlon Medical Inc (AEMD) Through its Various Ratios - The Dwinnex
Aethlon Medical names James Frakes permanent CEO By Investing.com - Investing.com Canada
Aethlon Medical names James Frakes permanent CEO - Investing.com
Aethlon Medical Appoints James B. Frakes as CEO - TipRanks
Aethlon Medical Expands Equity Incentive Plan by 3 Million shares - Investing.com Canada
Examining Aethlon Medical Inc (AEMD) stock is warranted - US Post News
StockNews.com Begins Coverage on Aethlon Medical (NASDAQ:AEMD) - Defense World
Analysts’ New Coverage for September 29th (AEMD, AEZS, AWX, BGCP, BGI, BLPH, BPTH, CAC, CALA, CBFV) - Defense World
AEMD: Positive Takeaways from Life Science Investor Forum Presentation - Zacks Small Cap Research
Analysts’ New Coverage for September 21st (AEMD, AEZS, AWX, BGCP, BLPH, BPTH, CAC, CALA, CBFV, CCM) - Defense World
Aethlon Medical (NASDAQ:AEMD) Coverage Initiated at StockNews.com - Defense World
Quarterly Metrics: Quick and Current Ratios for Aethlon Medical Inc (AEMD) - The Dwinnex
AEMD’s Stock Market Expedition: Traversing Gains and Losses in 2023 - The InvestChronicle
Market cap of Aethlon Medical Inc [AEMD] reaches 5.44M – now what? - The DBT News
A look at AEMD’s current quarter earnings estimates - US Post News
Aethlon Hemopurifier study receives ethics approval in India - Investing.com
Aethlon Hemopurifier study receives ethics approval in India By Investing.com - Investing.com Australia
Immunotherapy Clinical TrialsA New Approach to Treating Cancer - StockTitan
Aethlon Receives Ethics Committee Approval for Hemopurifier® Cancer Trial in India - StockTitan
Breaking Medical Technology News: Aethlon Medical (NASDAQ: AEMD) to Present at Virtual Investor Conferences in September - Investorideas.com newswire
Aethlon Medical to Present at Virtual Investor Conferences in September - StockTitan
Innovation Driving Cancer's Solid Tumors Market - StockTitan
Aethlon Gains on Product News - Baystreet.ca
Aethlon begins patient enrollment in Hemopurifier cancer trial - Investing.com
Aethlon begins patient enrollment in Hemopurifier cancer trial By Investing.com - Investing.com UK
Aethlon Medical Announces Activation of Royal Adelaide Hospital to Begin Patient Screening and Enrollment in Hemopurifier® Cancer Trial - StockTitan
Aethlon Medical to Present at the Life Sciences Investor Forum September 19th - ForexTV.com
Breaking Medical Technology News: Aethlon Medical (NASDAQ: AEMD) to Present at the Life Sciences Investor Forum September 19th - Investorideas.com newswire
Aethlon Medical (NASDAQ:AEMD) Now Covered by StockNews.com - Defense World
Was there any good news for Aethlon Medical Inc (AEMD) stock in the last session? - US Post News
Trading Day Review: Aethlon Medical Inc (AEMD) Gains Momentum, Closing at 0.37 - The Dwinnex
Aethlon Medical (NASDAQ:AEMD) Coverage Initiated by Analysts at StockNews.com - Defense World
Balance Sheet Insights: Aethlon Medical Inc (AEMD)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
A Look at Aethlon Medical Inc (AEMD) Shares in the Recent Past Indicates Growth - SETE News
Market Highlights: Aethlon Medical Inc (AEMD) Ends on a Low Note at 0.48 - The Dwinnex
Why Nordstrom Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket - Benzinga
Aethlon Medical, Inc. (NASDAQ:AEMD) Short Interest Up 119.8% in August - Defense World
Aethlon Medical's Hemopurifier shows promise in kidney study - Investing.com India
Aethlon Medical's Hemopurifier shows promise in kidney study By Investing.com - Investing.com Australia
Aethlon Medical Announces Publication of Preclinical Data Showing Ability of the Hemopurifier® to Remove Extracellular Vesicles and microRNAs from Renal Perfusates Following Controlled Oxygenated Rewarming of Discarded Donor Kidneys - StockTitan
A closer look at Aethlon Medical Inc (AEMD)’s stock price trends - US Post News
Aethlon Medical (NASDAQ:AEMD) Now Covered by Analysts at StockNews.com - Defense World
Get in on Aethlon Medical Inc’s (AEMD) buy-in window today! - SETE News
Aethlon Medical Inc Stock (AEMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.47%
1.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):